🎯 What are Aprea Therapeutics's current clinical trials and their expected outcomes?

Aprea Therapeutics is currently conducting several clinical trials for its lead programs, APR-1051 and ATRN-119. Here's an overview of their current clinical trials and expected outcomes:

1. **APR-1051 (WEE1 Inhibitor) Clinical Trials**:
- **ACESOT-1051 Trial**: This is a Phase 1 trial evaluating single-agent APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations. Early evidence of disease control has been observed, with three patients achieving stable disease in the 70 mg and 100 mg cohorts. The trial is ongoing, and future arms may explore APR-1051 in combination with checkpoint inhibitors.
- **Collaboration with MD Anderson**: Aprea has partnered with MD Anderson Cancer Center to explore APR-1051's efficacy in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress. This collaboration aims to generate data supporting APR-1051's therapeutic potential, especially in combination with immune checkpoint inhibitors.
2. **ATRN-119 (ATR Inhibitor) Clinical Trials**:
- **ABOYA-119 Trial**: This is a Phase 1 trial evaluating the potent ATR inhibitor ATRN-119 in patients with advanced solid tumors. Seven patients have achieved stable disease to date, including three with meaningful tumor shrinkage at the 550 mg twice daily dose. This trial is ongoing, and Aprea is exploring a twice-daily dosing regimen to optimize clinical outcomes.

**Expected Outcomes**:
- **APR-1051**: Aprea plans to submit abstracts to major oncology conferences and intends to share future data that could inform combination-based clinical trials.
- **ATRN-119**: Ongoing dose escalation studies are expected to provide further safety and efficacy data, potentially supporting future clinical development strategies.

These clinical trials are critical for Aprea Therapeutics, as they have the potential to demonstrate the efficacy of their lead programs and pave the way for regulatory approvals and commercialization. However, it's important to note that clinical trials are inherently uncertain, and outcomes may vary based on various factors including patient enrollment, treatment responses, and adverse event profiles.